1. Home
  2. VIGL vs DHX Comparison

VIGL vs DHX Comparison

Compare VIGL & DHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • VIGL
  • DHX
  • Stock Information
  • Founded
  • VIGL 2020
  • DHX 1991
  • Country
  • VIGL United States
  • DHX United States
  • Employees
  • VIGL N/A
  • DHX N/A
  • Industry
  • VIGL Biotechnology: Pharmaceutical Preparations
  • DHX Business Services
  • Sector
  • VIGL Health Care
  • DHX Consumer Discretionary
  • Exchange
  • VIGL Nasdaq
  • DHX Nasdaq
  • Market Cap
  • VIGL 95.2M
  • DHX 86.0M
  • IPO Year
  • VIGL 2022
  • DHX 2007
  • Fundamental
  • Price
  • VIGL $1.70
  • DHX $1.84
  • Analyst Decision
  • VIGL Buy
  • DHX Strong Buy
  • Analyst Count
  • VIGL 6
  • DHX 2
  • Target Price
  • VIGL $16.60
  • DHX $5.25
  • AVG Volume (30 Days)
  • VIGL 387.1K
  • DHX 103.5K
  • Earning Date
  • VIGL 11-07-2024
  • DHX 02-05-2025
  • Dividend Yield
  • VIGL N/A
  • DHX N/A
  • EPS Growth
  • VIGL N/A
  • DHX N/A
  • EPS
  • VIGL N/A
  • DHX 0.03
  • Revenue
  • VIGL N/A
  • DHX $144,428,000.00
  • Revenue This Year
  • VIGL N/A
  • DHX N/A
  • Revenue Next Year
  • VIGL N/A
  • DHX N/A
  • P/E Ratio
  • VIGL N/A
  • DHX $62.47
  • Revenue Growth
  • VIGL N/A
  • DHX N/A
  • 52 Week Low
  • VIGL $1.60
  • DHX $1.45
  • 52 Week High
  • VIGL $6.06
  • DHX $2.98
  • Technical
  • Relative Strength Index (RSI)
  • VIGL 23.30
  • DHX 55.09
  • Support Level
  • VIGL $1.60
  • DHX $1.70
  • Resistance Level
  • VIGL $2.46
  • DHX $1.91
  • Average True Range (ATR)
  • VIGL 0.16
  • DHX 0.10
  • MACD
  • VIGL -0.02
  • DHX 0.01
  • Stochastic Oscillator
  • VIGL 11.63
  • DHX 81.08

About VIGL Vigil Neuroscience Inc.

Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.

About DHX DHI Group Inc.

DHI Group Inc is a provider of artificial intelligence-powered software products, online tools and services to deliver career marketplaces to candidates and employers globally. DHI's brands includes Dice and ClearanceJobs enable recruiters and hiring managers to efficiently search, match and connect with skilled technologists in specialized fields, particularly technology and those with active government security clearances. The company derive the majority of revenue came from the sale of recruitment packages, which allow customers to promote jobs on our websites and source candidates through their resume databases. Recruitment packages are typically provided through contractual arrangements with annual, quarterly or monthly payment terms.

Share on Social Networks: